Treats multidrug resistant HIV-1. Sold as Sunlenca, Yeztugo. Every FDA application for this active ingredient.
As of Nov 16, 2026, FDA lists 4 applications for Lenacapavir Sodium (sold as Sunlenca, Yeztugo), first approved Dec 22, 2022, with 4 new uses approved and 2 published complete response letters.
| Sunlenca | Part D | $28.1M | +53% | 905 |
| YEZTUGO(J0738) | Part B | $1.8M | New | 170 |
| Sunlenca | Part B | $1.2M | +55% | 75 |
| YEZTUGO(J0752) | Part B | $295K | New | 167 |
| Dec 22, 2022 | SunlencaNDA 215973 · New molecular entity | Gilead Sciences Inc | 5 | Marketed |
| Dec 22, 2022 | SunlencaNDA 215974 · New molecular entity | Gilead Sciences Inc | 5 | Marketed |
| Jun 18, 2025 | YeztugoNDA 220018 · New indication | Gilead Sciences Inc | 0 | Marketed |
| Jun 18, 2025 | YeztugoNDA 220020 · New indication | Gilead Sciences Inc | 0 | Marketed |
| Feb 28, 2022 | LenacapavirProduct Quality | Approved |
| Feb 28, 2022 | LenacapavirProduct Quality, Ccit | Approved |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA